Inhaled Technosphere Insulin for Individualized Diabetes Management: 3 Case Reports of CGM Outcomes

Ebekozien O Mungmode A Sanchez J , et al. Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023;25(11):765-773. doi:10.1089/dia.2023.0320

Afrezza (insulin human) inhalation powder prescribing information. MannKind Corporation.

Cassidy JP Amin N Marino M , et al. Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharm Res. 2011;28(9):2157-64. doi:10.1007/s11095-011-0443-4

Association of Diabetes Care & Education Specialists. Insulin cost-saving resource guide. Updated July 7, 2022. Accessed March 9, 2024. https://www.adces.org/docs/default-source/practice/educator-tools/insulin-cost-saving-resource.pdf

Bode BW McGill JB Lorber DL , et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38(12):2266-2273. doi:10.2337/dc15-0075

Seaquist ER Blonde L McGill JB , et al. Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus. Diabet Med. 2020;37(5):752-759. doi:10.1111/dme.14202

Battelino T Danne T Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028

Akturk HK Snell-Bergeon JK Rewers A , et al. Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT Study. Diabetes Technol Ther. 2018;20(10):639-647. doi:10.1089/dia.2018.0200

Nicolucci A Ceriello A Di Bartolo P Corcos A Orsini Federici M. Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther. 2020;11(3):573-584. doi:10.1007/s13300-019-00732-w

Kaiserman KB Christiansen M Bhavsar S , et al. Reduction in postprandial peak glucose with increased Technosphere insulin dosage. J Diabetes Sci Technol. 2024;18(2):397-401. doi:10.1177/19322968221110622

Topp CW 0stergaard SD Sondergaard S Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-176. doi:10.1159/000376585

Grant M Heise T Baughman R. Comparison of pharma-cokinetics and pharmacodynamics of inhaled Technosphere insulin and subcutaneous insulin Lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet. 2022;61(3):413-422. doi:10.1007/s40262-021-01084-0

Kaiserman KB Codorniz K Lee S , et al. Inhaled insulin + AID safely reduced glucose in the 2 hours following a meal in proof of concept study data subset. Poster presented at: 22nd Annual Diabetes Technology Meeting; November 3-5, 2022. https://www.diabetestechnology.org/dtm/app/posters/Kaiser-man.pdf